• Home
  • >
  • Bafna Pharmaceuticals Ltd Financials
https://storage.googleapis.com/assets.cdp.blinkx.in/Blinkx_Website/icons/bafna-pharmaceuticals-ltd.png Logo

Bafna Pharmaceuticals Ltd Financial Statement

Bafna Pharmaceuticals Ltd Income Statement
Quarterly
Annual

*All values are in Rs. Cr

(Rs. CR)Dec 2023Sep 2023Jun 2023
Revenue29.4240.8443.82
Operating Expense30.5236.6735.65
Net Profit-2.942.486.35
Net Profit Margin-9.996.0714.49
Earning Per Share-1.241.052.68
EBIDTA-1.094.168.16
Effective Tax RateTBATBATBA

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

Bafna Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2020Mar 2019Mar 2018
Total Revenue Annual42.4743.6347.17
Operating Expenses Annual41.2556.782.3
Operating Profit Annual-21.08-11.68-3.8
Interest Annual0.12.136.94
Depreciation3.273.483.97
Net Profit Annual-24.73-18.87-16.74
Tax AnnualTBA1.072.19

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

Bafna Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2020Mar 2019Mar 2018
Cash Flow at the Beginning2.712.952.66
Cash Flow from Operations-34.31-1.79-7.05
Cash Flow from Investing32.7715.3637.97
Cash Flow from Financing7.3-13.81-30.63
Cash Flow at the End8.482.712.95

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

Bafna Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2020Mar 2019Mar 2018
PBDIT Margin (%)3.48-26.77-71.73
PBIT Margin (%)-4.22-34.75-80.15
PBT Margin (%)37.72-18.45-68.6
Net PROFIT Margin (%)-59.34-45.22-34.87
Return On Networth / Equity (%)TBATBATBA
Return On Networth /Employed(%)TBATBATBA
Return On Assets (%)-42.13-24.42-13.95
Total Debt / Equity(X)0.691.511.51
Asset Turnover Ratio (%)0.710.540.4

Particulars

PBDIT Margin (%)

PBIT Margin (%)

PBT Margin (%)

Net PROFIT Margin (%)

Return On Networth / Equity (%)

Return On Networth / Employed(%)

Return On Assets (%)

Total Debt / Equity(X)

Asset Turnover Ratio (%)

Bafna Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2020Mar 2019Mar 2018
Fixed Assets Annual3537.0544.9
Total Current Assets Annual36.148.4748.74
Non Current Assets Annual35.227189.62
Total Shareholders Funds Annual51.1119.0637.93
Total Assets Annual71.31119.47138.36

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

Bafna Pharmaceuticals Ltd Earning Calls
Sep 2019
EPS beaten by 0.00 %

Open Demat Account

50years
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

PE Ratio

Get Your FAQs Right

As of May 28, 2024, Bafna Pharmaceuticals Ltd has a market capitalization of 25.9 Cr. Value Research classifies it as a Micro-Cap company.

No, Bafna Pharmaceuticals Ltd is not debt-free with a debt-to-equity ratio of 2.43.

In FY 2023, Bafna Pharmaceuticals Ltd recorded a total revenue of approximately 43.36 Cr marking a significant milestone in the company's financial performance.

Bafna Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.4% and -0.2% annually, respectively..

Bafna Pharmaceuticals Ltd's current PE ratio is -1.41.

Bafna Pharmaceuticals Ltd's ROCE averaged -7.7% from the FY ending March 2017 to 2019, with a median of 0.0%. It peaked at 0.0% in March 2018, reflecting strong capital efficiency over the period..

Bafna Pharmaceuticals Ltd's latest EBIT is Rs. -15.15 Cr, surpassing the average EBIT of Rs. -10.61 Cr over the 5 years..